Blog

Molecular profiling of sqNSCLC reveals high incidence of actionable genomic alterations among patients with no history of smoking

Stephen V Liu/X

Jan 22, 2025, 10:25

Molecular profiling of sqNSCLC reveals high incidence of actionable genomic alterations among patients with no history of smoking

Yakup Ergün, Medical Oncologist at Antalya City Hospital, shared a post on X:

“Comprehensive profiling of sqNSCLC

AGAs were detected in 22.2% of never-smokers

Never-smokers with sqNSCLC had a significantly higher prevalence of actionable MET (9.5% vs 0.4%) and EGFR mutations (7.9% vs 0.4%) compared to ever-smokers.”

Comprehensive molecular profiling of squamous non-small cell lung cancer reveals high incidence of actionable genomic alterations among patients with no history of smoking

Authors: Joshua E. Reuss, Jacob Zaemes, Nishant Gandhi, Phillip Walker, Sandip P. Patel, Joanne Xiu, Charu Aggarwal, Ari Vanderwalde, Suresh S. Ramalingam, Balazs Halmos, Stephen V. Liu

Molecular profiling of sqNSCLC reveals high incidence of actionable genomic alterations among patients with no history of smoking

Ari Vanderwalde Balazs Halmos cancer Charu Aggarwal Jacob Zaemes Joanne Xiu Joshua E. Reuss Nishant Gandhi OncoDaily Oncology Phillip Walker Sandip P Patel Stephen V Liu Suresh S. Ramalingam Yakup Ergün

OncoDaily Acquires CancerWorld: A New Era in Oncology Media

FDA approved sotorasib with panitumumab for KRAS G12C-mutated colorectal cancer

Oncologist Near Me - Vivek Subbiah: Pionner of Precision Oncology

Monica Bertagnolli is ending her tenure as NIH director

Karen Knudsen: Clinical trials are the most advanced form of cancer care